BioMarin Announced Positive Final Results from Vosoritide Phase 3 pivotal trial. (BMN111-301)
BioMarin Announces Positive Final Results from Placebo-Controlled Phase 3 Data in Children with Achondroplasia Treated with Vosoritide Placebo-adjusted Increase in Growth Velocity of 1.6 cm/yr (p<0.0001) in Children Treated with…